J. Perotin-Collard (Reims, France), T. Tran Quoc (Ho Chi Minh, Vietnam), H. Kankaanranta (Seinäjoki, Finland), A. Maitland-van der Zee (Amsterdam, Netherlands)
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
H. Ohbayashi (Gifu, Japan), S. Kudo (Gifu, Japan), M. Ariga (Gifu, Japan)
|   |
Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI
V. Backer (Copenhagen, Denmark), O. Schmidt (Koblenz, Germany), B. Langer-Brauburger (Limburg, Germany), T. Schmidt (Limburg, Germany), C. Bennett (Cambridge, United Kingdom), D. Lindner (Limburg, Germany), S. Cuadripani (Cambridge, United Kingdom), B. Grothe (Cambridge, United Kingdom), T. Overend (Cambridge, United Kingdom)
| |
Efficacy of weight-based reslizumab dosing is consistent across body weights in post-hoc analysis
K. Murphy (Boys Town, United States of America), R. Noble (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America)
| |
Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients
P. Paggiaro (Pisa, Italy), G. Georges (Cary, United States of America), M. Scuri (Parma, Italy), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), S. Corre (Parma, Italy), A. Papi (Ferrara, Italy)
| |
Management of severe allergic asthma in the UK: Which monoclonal antibody would you choose?
T. Khalid (Bradford, United Kingdom), B. Clarke (Bradford, United Kingdom), P. Vivian (Bradford, United Kingdom), J. Walker (Bradford, United Kingdom), D. Saralaya (Bradford, United Kingdom)
| |
Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study
N. Hanania (Houston, United States of America), J. Fang (East Hanover, United States of America), Z. Wei (Morristown, United States of America), B. Ortiz (East Hanover, United States of America), A. Kavati (East Hanover, United States of America), X. Jaumont (Basel, Switzerland), L. Alvares (Basel, Switzerland), H. Cao (East Hanover, United States of America)
| |
Steroid inhaler dose reduction in comparison with montelukast discontinuation in asthma patients controlled by steroid inhaler and montelukast
H. Abtahi (Tehran, Islamic Republic of Iran), B. Rahimi (Tehran, Islamic Republic of Iran), S. Amini (Tehran, Islamic Republic of Iran)
| |
Intravenous (IV) reslizumab efficacy does not differ by blood eosinophil lowering to levels above or below 50 cells/µL
Y. Adir (Haifa, Israel), M. Castro (St Louis, United States of America), P. Chanez (Marseille, France), M. Mcdonald (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America)
| |
Immunogenicity assessment of intravenous administration of reslizumab in patients with asthma in phase 3 clinical studies
L. Zou (West Chester, United States of America), L. Pukac (West Chester, United States of America), Y. Shalit (Petah Tikva, Israel), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America), P. Liu (West Chester, United States of America)
| |
Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review
A. Kaplan (Toronto, Canada), J. Fitzgerald (Vancouver, Canada), G. El Azzi (Ingelheim am Rhein, Germany), M. Engel (Ingelheim am Rhein, Germany), R. Buhl (Mainz, Germany)
| |
No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma
M. Carlsson (Mölndal, Sweden), M. Braddock (Cambridge, United Kingdom), Y. Li (Gaithersburg, United States of America), J. Wang (Gaithersburg, United States of America), W. Xu (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America)
| |
Adherence to inhaled steroids treatment using smart nebulisers in severe asthmatics
B. Müllinger (Gauting, Germany), G. Burgess (Chippenham, United Kingdom), A. Ribera (Cambridge, United Kingdom), S. Snape (Cambridge, United Kingdom)
| |
Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study
N. Kwon (Brentford, Middlesex, United Kingdom), K. Gemzoe (Stockley Park, Uxbridge, Middlesex, United Kingdom), S. Worsley (Stockley Park, Uxbridge, Middlesex, United Kingdom), N. Gunsoy (Stockley Park, Uxbridge, Middlesex, United Kingdom), S. Joksaite (Stockley Park, Uxbridge, Middlesex, United Kingdom), M. Van Dyke (Upper Providence, PA, United States of America), C. Bettinson (Stockley Park, Uxbridge, Middlesex, United Kingdom), F. Albers (Research Triangle Park, NC, United States of America)
| |
Long-term results of anti-IgE-therapy in severe uncontrolled child asthma.
S. Diakova (Moscow, Russian Federation), Y. Mizernitskyi (Moscow, Russian Federation), L. Sokolova (Moscow, Russian Federation), E. Sorokina (Moscow, Russian Federation), I. Zorina (Moscow, Russian Federation)
| |
Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients?
E. Zamarron De Lucas (Madrid, Spain), D. Romero Ribate (Madrid, Spain), J. Fernández-Lahera Martínez (Madrid, Spain), C. Villasante Fernández-Montes (Madrid, Spain), S. Quirce Gancedo (Madrid, Spain), P. Barranco Sanz (Madrid, Spain), J. Domínguez Ortega (Madrid, Spain), R. Álvarez-Sala Walther (Madrid, Spain)
| |
Reliever effect of extrafine BDP/F DPI in asthmatic patients after methacholine challenge
M. Corradi (Parma, Italy), D. Singh (Manchester, United Kingdom), F. Van Den Berg (London, United Kingdom), B. Leaker (London , United Kingdom), S. Jabbal (Dundee, United Kingdom), S. Collarini (Parma, Italy), V. Mongelli (Parma, Italy), L. Santoro (Parma, Italy), A. Piccinno (Parma, Italy), S. Biondaro (Parma, Italy), B. Lipworth (Dundee, United Kingdom)
| |
Analysis of cytogenetic alterations in asthmatic patients treated with beclometasone dipropionate
A. Lintsov (St.Petersburg, Russian Federation), B. Uslontsev (St.Petersburg, Russian Federation), N. Pleskach (St.Petersburg, Russian Federation), V. Mikhelson (St.Petersburg, Russian Federation)
| |
Inhaled corticosteroids and asthma control in adult-onset asthma: 12-year follow-up study
I. Vähätalo (Seinäjoki, Finland), P. Ilmarinen (Seinäjoki, Finland), L. Tuomisto (Seinäjoki, Finland), O. Niemelä (Seinäjoki, Finland), H. Kankaanranta (Tampere, Finland)
| |
Intermittent tiotropium in early childhood wheezing? Preliminary safety results of a pilot study
A. Kotaniemi-Syrjänen (Helsinki, Finland), T. Klemola (Espoo, Finland), P. Koponen (Hyvinkää, Finland), H. Aito (Porvoo, Finland), K. Malmström (Helsinki, Finland), P. Malmberg (Helsinki, Finland), A. Pelkonen (Helsinki, Finland), M. Mäkelä (Helsinki, Finland)
| |
Consistent efficacy across endpoints with reslizumab despite short term variability in blood eosinophil levels
M. Castro (St Louis, United States of America), Y. Adir (Haifa, Israel), P. Chanez (Marseille, France), M. Mcdonald (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America)
| |